Electrotransport agent delivery method and apparatus

• US 5,983,130 A
• Filed: 06/07/1995
• Issued: 11/09/1999
• Est. Priority Date: 06/07/1995
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Gupta, Suneel, Theeuwes, Felix, Lattin, Gary A., Haak, Ronald P., Phipps, J. Bradley
• Primary Examiner(s): Bockelman, Mark
• Application Number:
  US08/483,069
• Time in Patent Office: 1,616 Days
• Field of Search: 604/20-21, 604/501, 607/115
• US Class Current: 604/20
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/0448 Drug reservoir
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428

Abstract

An electrotransport agent delivery device for delivering a therapeutic agent through a body surface, and a method for increasing agent delivery efficiency, is provided. The device includes a current controller which delivers a pulsating electrotransport current and peak current density I_max, I_max being greater than a critical current density level I_c above which the body exhibits a non-transitory higher agent delivery efficiency. Methods for increasing electrotransport delivery efficiency (E) of an agent through a body surface by creation of a higher agent delivery efficiency state are also provided.

Claims

1. In an electrotransport device for delivering a therapeutic agent through a body surface, the delivery device having a source of electrical power, a counter electrode, and a donor reservoir containing the agent, the reservoir having a delivery area through which the agent is delivered through the body surface, the improvement comprising;

an applied electrotransport current controller, the controller being adapted to apply a pulsating electrotransport current to the reservoir and in turn to the body surface, each pulse of the pulsating current being characterized by a frequency, a duty cycle, a peak width, and a peak current, the peak current when divided by the area of the delivery area providing a peak current density, I_max, I_max being greater than a critical current density level, I_c, above which the body surface exhibits non-transitory higher agent delivery efficiency (E), the delivery efficiency (E) being equal to the rate of agent delivered through the body surface per unit of applied electrotransport current.

2. The device of claim 1, wherein the agent delivery efficiency (E) is more stable at current densities above the critical level I_c and less stable at current densities below the critical level I_c relative to an untreated body surface.

3. The method of claim 1, wherein the device is adapted to be applied to human skin and the controller controls I_max to provide a current density of at least 40 μ

A/cm².

4. The device of claim 1, wherein the agent is fentanyl and the controller controls the applied current density to a level in the range of above 40 μ

A/cm² for a period of at least about 10 msec.

5. The device of claim 1, wherein the agent is goserelin and the device current level provides a current density in the range of at least about 50 to 100 μ

A/cm² applied for a period of at least about 10 msec.

6. A device according to claim 1 wherein the agent is fentanyl.

7. The device of claim 6, wherein the controller varies the a duty cycle of the pulsed driving current in order to vary the agent delivery rate.

8. The device of claim 1, wherein the donor reservoir contains an intentionally added competitive species.

9. The device of claim 1, whereby the device delivers the agent through the body surface at a reduced rate.

14. The method of claim 1, wherein the pulsing frequency is in the range of about 0.1 to 100 Hz.

15. The method of claim 1, wherein the pulsing electrotransport driving current has a duty cycle of less than about 100%.

10. A method of increasing delivery efficiency (E) of an agent delivered through a body surface by electrotransport, the delivery efficiency (E) being equal to the rate of agent delivered through the body surface per unit of applied electrotransport current, comprising delivering the agent by electrotransport through the body surface by applying a pulsing electrotransport driving current, each pulse of the pulsing driving current having a characteristic maximum peak height, which, when divided by the area of the body surface provides a current density I_max, I_max being greater than a critical current density level, I_c, above which the body surface exhibits higher agent delivery efficiency, the delivery efficiency (E) being equal to the rate of agent delivered through the body surface per unit of applied electrotransport current a frequency and a duty cycle ranging from 1 to 100% wherein the driving current has a pulsing frequency in the range of about 0.1 to 100 Hz.

11. The method of claim 10, wherein the pulsing frequency is in the range of about 0.1 to 10 Hz.

12. The method of claim 10, wherein the pulsing electrotransport driving current has a duty cycle of less than about 100%.

13. A method of increasing delivery efficiency (E) of an agent delivered through a body surface by electrotransport, the delivery efficiency (E) being equal to the rate of agent delivered through the body surface per unit of applied electrotransport current, comprising delivering the agent by electrotransport through the body surface by applying a pulsing electrotransport driving current, the driving current having a pulsing frequency in the range of about 0.1 to 100 Hz.

16. A method of increasing delivery efficiency (E) of an agent delivered through a body surface by electrotransport using a pulsating driving current, the delivery efficiency (E) being equal to the rate of agent delivered through the body surface per unit of applied electric current, the method comprising the steps of:

(a) identifying a critical current density I_c, which current density is associated with said agent and said body surface, the critical current density being the ratio of peak current divided by drug delivery area, the agent delivery efficiency (E) being (i) higher when the agent is delivered at current densities above I_c and (ii) lower when the agent is delivered at current densities below I_c ;

(b) identifying a critical time (t_c) of exposure of said body surface to said critical current density; and

(c) delivering the agent by electrotransport through the body surface by applying an electrotransport driving current, the driving current having a current density which is above the critical level I_c, through the body surface for at least a sufficient period greater than t_c to transform the body surface to an enhanced agent delivery efficiency state which is characterized by said higher efficiency; and

(d) delivering agent through the body surface substantially only at said higher efficiency.

17. The method of claim 16, wherein the body surface comprises human skin and I_c is at least about 40 μ

A/cm².

18. The method of claim 16, wherein the agent is fentanyl, the body surface is human skin and I_c comprises a current density in the range of at least about 40 μ

A/cm² applied for a period of at least about 10 msec.

19. The method of claim 16, wherein the agent is goserelin and I_c comprises a current density in the range of at least about 50 μ

A/cm² applied for a period of at least about 10 msec.

20. The method of claim 16, wherein the pulsed current has a duty cycle, the method including the step of varying the duty cycle of the pulsed current in order to vary the agent delivery rate.